Influenza Vaccine Availability and Recommendations

Available Influenza Vaccine Products

The Centers for Disease Control and Prevention recommends that various inactivated influenza vaccines (IIVs) are expected to be available for the 2024-25 influenza season, all of which are trivalent (IIV3s) 1
Standard-dose Fluzone contains a certain amount of hemagglutinin (HA) per vaccine virus in a dose, with varying amounts for different age groups 1
Fluzone High-Dose (HD-IIV3) contains a higher amount of HA per vaccine virus and is specifically approved for persons aged ≥65 years 1, 3

Multiple influenza vaccine products are available from different manufacturers, including Afluria, Fluarix, and FluLaval 1, 4, 5
Flucelvax is a cell culture-based trivalent inactivated vaccine (ccIIV3) that offers an alternative manufacturing process 1
For persons aged ≥65 years, Fluad (aIIV3) is an adjuvanted alternative to Fluzone High-Dose 1

The Advisory Committee on Immunization Practices (ACIP) makes no preferential recommendation for the use of any one influenza vaccine over another when more than one licensed and recommended vaccine is available, except for selection of influenza vaccines for persons aged ≥65 years 1
Vaccination should not be delayed to obtain a specific product when an appropriate one is available 1
For adults aged ≥65 years, higher-dose or adjuvanted influenza vaccines are preferentially recommended 3

Solid organ transplant recipients aged 18-64 years who are receiving immunosuppressive medications may benefit from high-dose or adjuvanted vaccines, though standard-dose vaccines are acceptable alternatives 1, 3
For immunocompromised individuals who have received hematopoietic cell transplantation or solid organ transplantation, clinicians could consider administering 2 doses of high-dose trivalent inactivated vaccine 3